CT-P13 comparable to infliximab at 54 weeks for ankylosing spondylitis
Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS studyArthritis Res Ther. 2016 Jan 20;18(1):25
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
250 ankylosing spondylitis patients were randomized to receive 5mg/kg of either CT-P13 or Infliximab through intravenous infusion for 54 weeks. The purpose of this study was to compare CT-P13, a biosimilar drug, to a known efficacious treatment of this pathology to determine its efficacy, immunogenicity, pharmacokinetics, and safety. The findings displayed similar results between groups for all pa...
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.Continue